Agenus BOT+BAL Meets Primary Endpoint in Phase 2 Colon Cancer Trial
Agenus said its BOT+BAL treatment met the primary endpoint in a Phase 2 trial in microsatellite-stable colon cancer.
Related stories
Oracle Launches Six-Part US Dollar Bond Offering
Bloomberg reports Oracle has launched a six-part U.S. dollar high-grade bond offering.
M impact | EQUITY | Nov 02, 2026, 12:52 PM UTC
LS Power Proposes to Acquire EVgo for $2.00 Per Share
A SEC filing says LS Power proposes to acquire EVgo Inc. for $2.00 per share in cash.
M impact | EQUITY | Nov 02, 2026, 12:45 PM UTC
Herfy Foods Expects Tariffs to Raise Annual Cost of Revenue 1.2%
Herfy Foods expects higher electricity and water tariffs to increase its annual cost of revenue by 1.2%.
M impact | EQUITY | Nov 02, 2026, 12:44 PM UTC
PSEG Q3 Revenue Falls, Maintains 2026 Guidance
M impact | EQUITY | Nov 02, 2026, 12:44 PM UTC
Tiziana Says Experimental MS Treatment Meets Main Goals in Mid-Stage Study
Tiziana Life Sciences said its experimental therapy reduced brain inflammation and showed a favorable safety profile in a mid-stage trial for progressive multiple sclerosis.
L impact | EQUITY | Nov 02, 2026, 12:42 PM UTC
Loews Reports Q3 Revenue of $4.76 Billion, EPS of $1.50
Loews said third-quarter revenue rose 1.9% year over year to $4.76 billion. Net income attributable to shareholders fell 39.3% to $306 million, and diluted EPS declined 38.3% to $1
M impact | EQUITY | Nov 02, 2026, 12:41 PM UTC